EUVIMEDEUVIMED entdecken
Crossref

Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation

Ze Li, Siyu Yang, Zixin Hua, Yanxia Lu, Xingang Li

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-023-02798-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Ze Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing, 100050, China. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thrombosis, Factor Xa Inhibitors, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Research and application of clinical characteristic diagnosis and treatment technology in Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to develop a population pharmacokinetic (PPK) model for rivaroxaban and establish a model-based dosing guideline tailored to Chinese patients with deep vein thrombosis (DVT). A nonlinear mixed-effects modeling approach was employed using Phoenix NLME 7.0 software to construct the PPK model for rivaroxaban. The PK of rivaroxaban was adequately characterized through a one-compartment model. Monte Carlo simulations were employed to formulate dosing guidelines applicable to different patient subgroups. Data from 60 Chinese DVT patients yielded 217 rivaroxaban plasma concentrations for analysis. The apparent clearance (CL/F) of rivaroxaban was found to be significantly influenced by the estimated glomerular filtration rate (eGFR), identified as a major covariate. Based on Monte Carlo simulations, for the acute DVT treatment, a regimen of 15 mg, 10 mg, or 5 mg twice daily was associated with the highest total probability target attainment (PTAtotal) in patients with normal, mildly impaired, or moderately impaired renal function, respectively. For the continued DVT treatment, a regimen of 20 mg, 15 mg, or 5 mg once daily exhibited the maximum PTAtotal in patients with normal, mildly impaired, or moderately impaired renal function, respectively. The recommendation label dose achieved the PK target in those with normal renal function. However, for patients with mild or moderate renal impairment, dose adjustments below the label recommendation might be necessary. The PPK model associated CL/F with the covariate eGFR. Utilizing the PPK model, a dosage regimen table was constructed to offer tailored dosing recommendations for Chinese DVT patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanVenous ThrombosisFactor Xa InhibitorsModels, BiologicalMonte Carlo MethodHumansMaleFemaleMiddle AgedAgedAdultGlomerular Filtration RateComputer SimulationChinaDose-Response Relationship, DrugYoung AdultEast Asian People

Stichwörter der Autor:innen

Deep vein thrombosisDosing guidelineEstimated glomerular filtration ratePopulation pharmacokineticsRivaroxaban

Substanzen

RivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing, 100050, China.
  • Department of Pharmacy, Medical Supplies Center of Chinese, PLA General Hospital, No. 69 Yongding Road, Haidian District, Beijing, 100039, China. lyx_67386@sina.com.
  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing, 100050, China. lxg198320022003@163.com.

Förderung

  • Research and application of clinical characteristic diagnosis and treatment technology in Beijing

Zitieren

APA

Li, Z., Yang, S., Hua, Z., Lu, Y., & Li, X. (2024). Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02798-7

Vancouver

Li Z, Yang S, Hua Z, Lu Y, Li X. Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02798-7

BibTeX
@article{Li2024,
  author = {Li, Ze and Yang, Siyu and Hua, Zixin and Lu, Yanxia and Li, Xingang},
  title = {Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-023-02798-7}
}
Kostenlos starten →